Peanut allergen-specific immunoglobulin E (Peanut sIgE)

Peanut allergen-specific immunoglobulin E (IgE) is a polyclonal antibody population that recognizes specific peanut proteins, most notably Ara h 1, Ara h 2, and Ara h 3 (Sampson et al., 2018). In sensitized individuals, these IgE molecules are predominantly bound to the high-affinity IgE receptor (FcεRI) on the surface of effector immune cells, such as mast cells and basophils. Upon re-exposure to peanut allergens, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes. This process can lead to symptoms ranging from mild urticaria to life-threatening anaphylaxis (Galli et al., 2012). This molecular complex is the primary driver of peanut allergy and serves as a critical therapeutic target for both biologics and immunotherapy. Drugs like omalizumab work by neutralizing free IgE and subsequently downregulating FcεRI expression on effector cells (Saini et al., 2011). Oral immunotherapy (OIT) aims to modulate the immune response toward tolerance by altering the IgE-mediated signaling threshold through controlled allergen exposure (Wood et al., 2024). Understanding the dynamics of peanut-specific IgE is crucial for managing the risk of severe reactions and developing next-generation treatments.

Other names

Peanut-specific IgEAra h-specific IgEEffector cell-bound IgEPolyclonal peanut IgEPeanut sIgE-FcεRI complex

Anti-IgE monoclonal antibodies like omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (Saini et al., 2011). This sequestration reduces the density of FcεRI on effector cells, raising the threshold for allergen-induced activation (MacGlashan et al., 1997). Oral immunotherapy (OIT) utilizes the allergen itself to induce desensitization, characterized by a decrease in peanut-specific IgE/IgG4 ratios and reduced basophil reactivity (Vickery et al., 2019).